| First Author | Yu Y | Year | 2022 |
| Journal | J Biol Chem | Volume | 298 |
| Issue | 4 | Pages | 101759 |
| PubMed ID | 35202649 | Mgi Jnum | J:324576 |
| Mgi Id | MGI:7260803 | Doi | 10.1016/j.jbc.2022.101759 |
| Citation | Yu Y, et al. (2022) Angiogenic factor AGGF1 blocks neointimal formation after vascular injury via interaction with integrin alpha7 on vascular smooth muscle cells. J Biol Chem 298(4):101759 |
| abstractText | Angiogenic factor AGGF1 (AngioGenic factor with G-patch and FHA (Forkhead-Associated) domain 1) blocks neointimal formation (formation of a new or thickened layer of arterial intima) after vascular injury by regulating phenotypic switching of vascular smooth muscle cells (VSMCs). However, the AGGF1 receptor on VSMCs and the underlying molecular mechanisms of its action are unknown. In this study, we used functional analysis of serial AGGF1 deletions to reveal the critical AGGF1 domain involved in VSMC phenotypic switching. This domain was required for VSMC phenotypic switching, proliferation, cell cycle regulation, and migration, as well as the regulation of cell cycle inhibitors cyclin D, p27, and p21. This domain also contains an RDDAPAS motif via which AGGF1 interacts with integrin alpha7 (ITGA7), but not alpha8. In addition, we show that AGGF1 enhanced the expression of contractile markers MYH11, alpha-SMA, and SM22 and inhibited MEK1/2, ERK1/2, and ELK phosphorylation in VSMCs, and that these effects were inhibited by knockdown of ITGA7, but not by knockdown of ITGA8. In vivo, deletion of the VSMC phenotypic switching domain in mice with vascular injury inhibited the functions of AGGF1 in upregulating alpha-SMA and SM22, inhibiting MEK1/2, ERK1/2, and ELK phosphorylation, in VSMC proliferation, and in blocking neointimal formation. Finally, we show the inhibitory effect of AGGF1 on neointimal formation was blocked by lentivirus-delivered shRNA targeting ITGA7. Our data demonstrate that AGGF1 interacts with its receptor integrin alpha7 on VSMCs, and this interaction is required for AGGF1 signaling in VSMCs and for attenuation of neointimal formation after vascular injury. |
